Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology NASDAQ
$437.67
+$1.08 (+0.25%)
Open: $437.38 | High: $441.00 | Low: $435.45 | Prev Close: Prev Close: $436.59
Market Cap: $111.33B
Volume: 695K | Avg: 1.4M
Last updated: April 23, 2026 at 08:04 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 580
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 28.57 |
| P/B Ratio | 5.95 |
| P/S Ratio | 9.25 |
| EPS | $15.32 |
| Beta | 0.37 |
| Shares Outstanding | 254.36M |
| 52-Week High | $510.77 |
| 52-Week Low | $362.50 |
| SMA 50 | $459.56 |
| SMA 200 | $437.72 |
| Next Earnings | May 04, 2026 08:00 PM ET |
Financial Ratios
| Gross Margin | 86.3% |
| Operating Margin | 35.5% |
| Net Margin | 32.8% |
| ROE | 22.7% |
| ROA | 15.1% |
| Debt/Equity | 0.21 |
| Current Ratio | 2.90 |
| Quick Ratio | 2.46 |
Balance Sheet
| Total Assets | $26.14B |
| Total Liabilities | $7.48B |
| Total Equity | $18.67B |
|
|
|
| Cash | $5.09B |
| Total Debt | $3.88B |
| Net Debt | $-1,205,300,000 |
Income Statement
| Revenue | $12.07B |
| Gross Profit | $10.27B |
| Operating Income | $4.76B |
| Net Income | $3.95B |
|
|
|
| EBITDA | $4.97B |
| Revenue/Share | $47.41 |
Cash Flow
| Operating CF | $3.63B |
| CapEx | $437.60M |
| Free Cash Flow | $3.19B |
|
|
|
| Book Value/Share | $73.52 |
| Tangible Book/Share | $67.56 |
| Equity/Share | $73.52 |
Technical Indicators
| RSI (14) | 43.26 Neutral |
| MACD |
-7.29
Signal: -7.76
|
| Volatility | 35.00% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -3.2% |
| Sharpe Ratio | -0.08 Poor |
| Volatility (Ann.) | 36.49% Moderate |
| VRTX (1Y) | -3.2% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | -17.61% |
Sector Comparison (Healthcare)
| Metric | VRTX | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 28.57 | 26.19 | 60% |
| P/B Ratio | 5.95 | -21.14 | 74% |
| ROE (%) | 22.70% | -10.35% | 72% |
| Net Margin (%) | 32.84% | 8.96% | 98% |
| Stock Score | 580 | 548.0 | 62% |
| 1Y Return (%) | -3.20 % | +5.31 % | 45% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | $437.67 | $438.76 | $438.42 | $439.98 | $462.21 | $438.32 | 43.26 | -7.29 | 35.00% | 734332 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the VRTX stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why | Positive | zacks.com | Read More |
| VRTX | Cwm LLC Grows Stock Position in Vertex Pharmaceuticals Incorporated $VRTX | Neutral | defenseworld.net | Read More |
| VRTX | 3 Healthcare Stocks With the Most Durable Competitive Moats | Neutral | fool.com | Read More |
| VRTX | Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know | Neutral | zacks.com | Read More |
| VRTX | Merit Financial Group LLC Buys 2,880 Shares of Vertex Pharmaceuticals Incorporated $VRTX | Neutral | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-01 | Liu Joy | officer: EVP and Chief Legal Officer | SELL | 978 | $449.17 | $439288 |
| 2026-03-27 | Bozic Carmen | officer: EVP and CMO | SELL | 2329 | $450.95 | $1050263 |
| 2026-03-13 | Bozic Carmen | officer: EVP and CMO | SELL | 2329 | $481.79 | $1122089 |
| 2026-03-11 | McKechnie Duncan | officer: EVP, Chief Commercial Officer | SELL | 2633 | $498.42 | $1312340 |
Company Information
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| CEO | Reshma Kewalramani |
| Employees | 6100 |
| Country | US |
| IPO Date | 1991-07-24 |
| Exchange | NASDAQ |
| Website | https://www.vrtx.com |
| Sector | Healthcare |
| Industry | Biotechnology |
Similar Stocks (Healthcare - Biotechnology)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category